Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury

心脏损伤后心脏祖细胞的比较疗效和作用机制

阅读:4
作者:Muthukumar Gunasekaran ,Rachana Mishra ,Progyaparamita Saha ,David Morales ,Wen-Chih Cheng ,Arun R Jayaraman ,Jessica R Hoffman ,Lauran Davidson ,Ling Chen ,Aakash M Shah ,Gregory Bittle ,Xuebin Fu ,Antariksh Tulshyan ,Mohamed Abdullah ,Tami Kingsbury ,Curt Civin ,Peixin Yang ,Michael E Davis ,Roberto Bolli ,Joshua M Hare ,Sudhish Sharma ,Sunjay Kaushal

Abstract

Successful cell therapy requires cells to resist the hostile ischemic myocardium, be retained to continue secreting cardioprotective growth factors/exosomes, and resist immunological host responses. Clinically relevant stem/progenitor cells in a rodent model of acute myocardial infarction (MI) demonstrated that neonatal cardiac mesenchymal stromal cells (nMSCs) provide the most robust cardiac functional recovery. Transplanted nMSCs significantly increased the number of tissue reparative macrophages and regulatory T-cells and decreased monocyte-derived inflammatory macrophages and neutrophils in the host myocardium. mRNA microarray and single-cell analyses combined with targeted depletion studies established CD47 in nMSCs as a key molecule responsible for cell retention in the myocardium through an antiphagocytic mechanism regulated by miR34a-5p. Gain and loss-of-function studies demonstrated that miR34a-5p also regulated the production of exosomes and cardioprotective paracrine factors in the nMSC secretome. In conclusion, miR34a-5p and CD47 play an important role in determining the composition of nMSCs' secretome and immune evasion, respectively.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。